是时候重估信达生物了

建国路128号
Feb 11

如果说去年10月,信达与武田达成的百亿美元级合作,让市场第一次意识到信达生物在全球创新药牌桌上的位置;那么,信达与礼来这笔总金额超85亿美元的重磅交易,则彻底验证了这家公司创新实力的进化。这个交易围绕一系列创新分子的选择权,礼来用一个首付款锁定若干款新产品临床验证后的权益。3.5亿美元的首付款,对于早期资产来说,几乎是天花板级别的定价。据管理层透露,这也是第七次和礼来的合作了,是一个基于平台的交易...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10